|
1
|
Friedman SL: Molecular regulation of
hepatic fibrosis, an integrated cellular response to tissue injury.
J Biol Chem. 275:2247–2250. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Milani S, Herbst H, Schuppan D, Surrenti
C, Riecken EO and Stein H: Cellular localization of type I III and
IV procollagen gene transcripts in normal and fibrotic human liver.
Am J Pathol. 137:59–70. 1990.PubMed/NCBI
|
|
3
|
Bataller R and Brenner DA: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taguchi T and Razzaque MS: The
collagen-specific molecular chaperone HSP47: Is there a role in
fibrosis. Trends Mol Med. 13:45–53. 2007. View Article : Google Scholar
|
|
5
|
Razzaque MS, Le VT and Taguchi T: Heat
shock protein 47 and renal fibrogenesis. Contrib Nephrol.
148:57–69. 2005.PubMed/NCBI
|
|
6
|
Chen JJ, Jin PS, Zhao S, Cen Y, Liu Y, Xu
XW, Duan WQ and Wang HS: Effect of heat shock protein 47 on
collagen synthesis of keloid in vivo. ANZ J Surg. 81:425–430. 2011.
View Article : Google Scholar
|
|
7
|
Brown KE, Broadhurst KA, Mathahs MM, Brunt
EM and Schmidt WN: Expression of HSP47, a collagen-specific
chaperone, in normal and diseased human liver. Lab Invest.
85:789–797. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakayama S, Mukae H, Sakamoto N, et al:
Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated
human lung fibroblasts. Life Sci. 82:210–217. 2008. View Article : Google Scholar
|
|
9
|
Sato Y, Murase K, Kato J, et al:
Resolution of liver cirrhosis using vitamin A-coupled liposomes to
deliver siRNA against a collagen-specific chaperone. Nat
Biotechnol. 26:431–442. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kakugawa T, Mukae H, Hayashi T, Ishii H,
Abe K, Fujii T, Oku H, Miyazaki M, Kadota J and Kohno S:
Pirfenidone attenuates expression of HSP47 in murine
bleomycin-induced pulmonary fibrosis. Eur Respir J. 24:57–65. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao XY, Zeng X, Li XM, Wang TL and Wang
BE: Pirfenidone inhibits carbon tetrachloride- and albumin
complex-induced liver fibrosis in rodents by preventing activation
of hepatic stellate cells. Clin Exp Pharmacol Physiol. 36:963–968.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Armendáriz-Borunda J, Rincón AR,
Muñoz-Valle JF, et al: Fibrogenic polymorphisms (TGF-beta, PAI-1,
AT) in Mexican patients with established liver fibrosis. Potential
correlation with pirfenidone treatment. J Investig Med. 56:944–953.
2008.PubMed/NCBI
|
|
13
|
Hewitson TD, Kelynack KJ, Tait MG, Martic
M, Jones CL, Margolin SB and Becker GJ: Pirfenidone reduces in
vitro rat renal fibroblast activation and mitogenesis. J Nephrol.
14:453–460. 2001.
|
|
14
|
Miric G, Dallemagne C, Endre Z, Margolin
S, Taylor SM and Brown L: Reversal of cardiac and renal fibrosis by
pirfenidone and spironolactone in streptozotocin-diabetic rats. Br
J Pharmacol. 133:687–694. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun G, Lin X, Zhong H, Yang Y, Qiu X, Ye
C, Wu K and Yu M: Pharmacokinetics of pirfenidone after topical
administration in rabbit eye. Mol Vis. 17:2191–2196.
2011.PubMed/NCBI
|
|
16
|
Lin X, Yu M, Wu K, Yuan H and Zhong H:
Effects of pirfenidone on proliferation, migration, and collagen
contraction of human Tenon’s fibroblasts in vitro. Invest
Ophthalmol Vis Sci. 50:3763–3770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Sario A, Bendia E, Svegliati Baroni G,
et al: Effect of pirfenidone on rat hepatic stellate cell
proliferation and collagen production. J Hepatol. 37:584–591. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gurujeyalakshmi G, Hollinger MA and Giri
SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model
of lung fibrosis at the translational level. Am J Physiol.
276:L311–L318. 1999.PubMed/NCBI
|
|
19
|
Grattendick KJ, Nakashima JM, Feng L, Giri
SN and Margolin SB: Effects of three anti-TNF-alpha drugs:
Etanercept, infliximab and pirfenidone on release of TNF-alpha in
medium and TNF-alpha associated with the cell in vitro. Int
Immunopharmacol. 8:679–687. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oku H, Nakazato H, Horikawa T, Tsuruta Y
and Suzuki R: Pirfenidone suppresses tumor necrosis factor-alpha,
enhances interleukin-10 and protects mice from endotoxic shock. Eur
J Pharmacol. 446:167–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ginès P, Cárdenas A, Arroyo V and Rodés J:
Management of cirrhosis and ascites. N Engl J Med. 350:1646–1654.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rockey DC: Current and future
anti-fibrotic therapies for chronic liver disease. Clin Liver Dis.
12:939–962. xi2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao W, Li JJ, Cao DY, Li X, Zhang LY, He
Y, Yue SQ, Wang DS and Dou KF: Intravenous injection of mesenchymal
stem cells is effective in treating liver fibrosis. World J
Gastroenterol. 18:1048–1058. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Behr J: Idiopathic pulmonary fibrosis:
Modern guideline-concordant diagnostics and innovative treatment.
Dtsch Med Wochenschr. 137:601–604. 2012.In German. PubMed/NCBI
|
|
25
|
Salazar-Montes A, Ruiz-Corro L,
López-Reyes A, Castrejón-Gómez E and Armendáriz-Borunda J: Potent
antioxidant role of pirfenidone in experimental cirrhosis. Eur J
Pharmacol. 595:69–77. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Di Sario A, Bendia E, Macarri G,
Candelaresi C, Taffetani S, Marzioni M, Omenetti A, De Minicis S,
Trozzi L and Benedetti A: The anti-fibrotic effect of pirfenidone
in rat liver fibrosis is mediated by downregulation of procollagen
alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis. 36:744–751. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tada S, Nakamuta M, Enjoji M, Sugimoto R,
Iwamoto H, Kato M, Nakashima Y and Nawata H: Pirfenidone inhibits
dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp
Pharmacol Physiol. 28:522–527. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Navarro-Partida J, Martinez-Rizo AB,
Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V and
Armendariz-Borunda J: Pirfenidone restricts Th2 differentiation in
vitro and limits Th2 response in experimental liver fibrosis. Eur J
Pharmacol. 678:71–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sauk JJ, Nikitakis N and Siavash H: Hsp47
a novel collagen binding serpin chaperone, autoantigen and
therapeutic target. Front Biosci. 10:107–118. 2005. View Article : Google Scholar
|
|
30
|
Taguchi T, Nazneen A, Al-Shihri AA,
Turkistani KA and Razzaque MS: Heat shock protein 47: A novel
biomarker of phenotypically altered collagen-producing cells. Acta
Histochem Cytochem. 44:35–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagata K: Therapeutic strategy for
fibrotic diseases by regulating the expression of collagen-specific
molecular chaperone HSP47. Nippon Yakurigaku Zasshi. 121:4–14.
2003.In Japanese. View Article : Google Scholar
|
|
32
|
Xia Z, Abe K, Furusu A, Miyazaki M, Obata
Y, Tabata Y, Koji T and Kohno S: Suppression of renal
tubulointerstitial fibrosis by small interfering RNA targeting heat
shock protein 47. Am J Nephrol. 28:34–46. 2008. View Article : Google Scholar
|
|
33
|
Hagiwara S, Iwasaka H, Shingu C, Matumoto
S, Hasegawa A and Noguchi T: Heat shock protein 47 (HSP47)
antisense oligonucleotides reduce cardiac remodeling and improve
cardiac function in a rat model of myocardial infarction. Thorac
Cardiovasc Surg. 59:386–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dams SD, de Liefde-van Beest M, Nuijs AM,
Oomens CW and Baaijens FP: Heat shocks enhance procollagen type I
and III expression in fibroblasts in ex vivo human skin. Skin Res
Technol. 17:167–180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sauk JJ, Smith T, Norris K and Ferreira L:
Hsp47 and the translation-translocation machinery cooperate in the
production of alpha 1(I) chains of type I procollagen. J Biol Chem.
269:3941–3946. 1994.PubMed/NCBI
|
|
36
|
Sunamoto M, Kuze K, Tsuji H, Ohishi N,
Yagi K, Nagata K, Kita T and Doi T: Antisense oligonucleotides
against collagen-binding stress protein HSP47 suppress collagen
accumulation in experimental glomerulonephritis. Lab Invest.
78:967–972. 1998.PubMed/NCBI
|
|
37
|
Hagiwara S, Nakamura K, Hamada H, et al:
Inhibition of type I procollagen production by tRNAVal CTE-HSP47
ribozyme. J Gene Med. 5:784–794. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nishino T, Miyazaki M, Abe K, Furusu A,
Mishima Y, Harada T, Ozono Y, Koji T and Kohno S: Antisense
oligonucleotides against collagen-binding stress protein HSP47
suppress peritoneal fibrosis in rats. Kidney Int. 64:887–896. 2003.
View Article : Google Scholar : PubMed/NCBI
|
